Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitazoxanide in Mild COVID-19
NCT04441398Phase 3Withdrawn
- Sponsor
- Azidus Laboratories Limited
- Start
- Jul 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Nitazoxanide Arm with Placebo Arm (2 arms). Primary endpoint: Change in signs and symptoms scale at 21 days. Planned start Jul 2020; status: withdrawn.
02
Drugs
nitazoxanide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04441398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04441398.